SAGA gains €3.7 million for cancer liquid biopsies

SAGA raises 40 million SEK (€3.7 million) to advance ultrasensitive cancer liquid biopsies

June 10, 2019
DDNews Staff
LUND, Sweden and OSLO, NorwaySAGA Diagnostics AB announced today the raising of SEK 40 million (around €3.7 million) in venture-backed financing. Hadean Ventures leads the round, and is joined by a number of existing shareholders including Fårö Capital and the Gunnar Nilsson Cancer Foundation
 
“We are very pleased to have Hadean Ventures on board, as one of the premier specialist life science venture funds in the Nordics,” said Lao Saal, CEO of SAGA Diagnostics. “We are looking forward to working with the Hadean team to help shape a new era in cancer diagnostics to improve cancer survivorship.”
 
SAGA’s technologies quantify aberrations in DNA, RNA, and circulating tumor DNA (ctDNA), and are uniquely capable of achieving limits of detection down to 0.001% mutant allele fraction. SAGA, as a spin-out from innovative research at Lund University, already has commercial agreements with a number of pharmaceutical partners and biomedical laboratories for the use of its proprietary technologies, central lab testing services and reagent kits.
 
The applications of the SAGA technologies are based on massively parallel sequencing and digital PCR, and include patient stratification, companion diagnostics, monitoring response to cancer therapies, identifying disease relapse and aiding treatment decisions for patients with cancers such as breast cancer, non-small cell lung cancer, colorectal cancer and acute myeloid leukemia.
 
Walter Stockinger, managing partner of Hadean Ventures and incoming board member of SAGA, noted that “We believe liquid biopsies will be an increasingly important part of treating cancer patients in the future. What attracted us to SAGA specifically is its unique platform technologies, which sets SAGA apart in an exciting and developing field.”
 
The funds will be used to accelerate commercialization of SAGA’s portfolio of kits and services, continue development of new products and perform prospective clinical studies. Regulatory activities towards laboratory ISO accreditation and the first CE-IVD marked kits are also underway.
 
“SAGA is an excellent example of the world class technology being developed in the Nordics that can help to solve global challenges in healthcare. We are proud to team up with SAGA and look forward to helping the team develop their products further,” added Ingrid Teigland Akay, managing partner of Hadean Ventures.
Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all the latest DDN news!

Latest Issue  

• Volume 17 • Issue 6 • June 2021

June 2021

June 2021 issue